Compounds that require bioavailability enhancement to achieve target absorption are increasingly common in current pipelines. These compounds must be paired with various technologies to enable progression.
This presentation will focus on the rationale for selecting these enabling technologies based on a technology agnostic approach using a compound’s physical properties (e.g., Tm, Tg, LogP) and product specifications (e.g., dose, pharmacokinetics, permeability). By using maps and guidances, it is possible to choose a lead formulation with little experimental work. This fundamental model-based approach reduces overall time to clinic vs. evaluating multiple technologies in a trial and error process.
With years of experience formulating these compounds, case studies will be presented that illustrate this process of technology and formulation selection based on using scientific fundamentals and not an empirical approach.
David Vodak, Ph.D, Vice President of Chemistry, Bend Research Inc.
Dr. Vodak is Vice President of Chemistry at Bend Research Inc. and has been with the company since 2004. His past positions have included Director of Research and Director of Physical and Biological Sciences.
Dr. Vodak’s areas of expertise at Bend Research include the research and development of novel Pharmaceutical drug-delivery systems with a focus on the delivery of low-solubility compounds and on a pulmonary platform based on spray-dried engineered particles. His other research has centered on the characterization and investigation of physical properties, stability, and solubility of technologies aimed at enhancing bioavailability such as, spray‑dried dispersions (SDDs), high energy nano-crystals (HENC), nanoadsorbates (NADDs), nanoparticles and spray‑layered dispersions (SLDs).
Dr. Vodak holds a Ph.D. in materials chemistry from the University of Michigan and a B.A. in chemistry from Willamette University. He is a member of the American Chemical Society and the American Association of Pharmaceutical Scientists, and he holds three patent applications.
Who Should Attend?
Senior level executives working with dosage forms for pharmaceutical and biotechnology companies worldwide
For more than 35 years, Bend Research has worked with clients to create value by advancing new medicines that improve human health and to solve their most difficult scientific and technical problems. This success is based on the company’s ability to develop, advance, and commercialize Pharmaceutical technologies, which grow from a solid base of scientific and engineering fundamental understanding. Bend Research is a leader in novel formulations, including SDDs and hot-melt extrusions, as well as controlled-release, inhalation, and biotherapeutics technologies.
Bend Research, now part of Capsugel’s Dosage Form Solutions business unit, has access to additional technologies, R&D capabilities and global manufacturing infrastructure for the advancement of client compounds from concept through clinical to commercial manufacture.
Bend Research has more than 250 employees based in four state-of-the-art facilities in Bend, Ore., USA, and is part of the global Capsugel network of 3,100 employees.